Melanoma - Pipeline Review, H2 2018
- Global Markets Direct
- December 2018
- 2285 pages
Melanoma - Pipeline Review, H2 2018
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.
Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 18, 126, 141, 1, 11, 223, 33 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 18, 16, 75 and 11 molecules, respectively.
Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Have query on this report?Make an Enquiry
Table of Contents
Table of Contents 2
Melanoma - Overview 13
Melanoma - Therapeutics Development 14
Melanoma - Therapeutics Assessment 80
Melanoma - Companies Involved in Therapeutics Development 114
Melanoma - Drug Profiles 240
Melanoma - Dormant Projects 2161
Melanoma - Discontinued Products 2195
Melanoma - Product Development Milestones 2200
List of Tables
Number of Products under Development for Melanoma, H2 2018 85
Number of Products under Development by Companies, H2 2018 87
Number of Products under Development by Universities/Institutes, H2 2018 108
Products under Development by Companies, H2 2018 113
Products under Development by Universities/Institutes, H2 2018 144
Number of Products by Stage and Target, H2 2018 152
Number of Products by Stage and Mechanism of Action, H2 2018 167
Number of Products by Stage and Route of Administration, H2 2018 182
Number of Products by Stage and Molecule Type, H2 2018 184
Melanoma - Pipeline by 4D Pharma PLC, H2 2018 185
Melanoma - Pipeline by 4P-Pharma SAS, H2 2018 185
Melanoma - Pipeline by 4SC AG, H2 2018 186
Melanoma - Pipeline by AB Science SA, H2 2018 186
Melanoma - Pipeline by AbbVie Inc, H2 2018 187
Melanoma - Pipeline by Abivax SA, H2 2018 187
Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2018 188
Melanoma - Pipeline by Aduro BioTech Inc, H2 2018 188
Melanoma - Pipeline by Advanced BioDesign, H2 2018 189
Melanoma - Pipeline by Advenchen Laboratories LLC, H2 2018 189
Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H2 2018 190
Melanoma - Pipeline by Afecta Pharmaceuticals Inc, H2 2018 190
Melanoma - Pipeline by Affichem SA, H2 2018 190
Melanoma - Pipeline by Agenus Inc, H2 2018 191
Melanoma - Pipeline by AGV Discovery SAS, H2 2018 191
Melanoma - Pipeline by AIMM Therapeutics BV, H2 2018 192
Melanoma - Pipeline by AiVita Biomedical Inc, H2 2018 192
Melanoma - Pipeline by Alkermes Plc, H2 2018 193
Melanoma - Pipeline by Allergy Therapeutics Plc, H2 2018 193
Melanoma - Pipeline by Alligator Bioscience AB, H2 2018 194
Melanoma - Pipeline by Altor BioScience Corp, H2 2018 194
Melanoma - Pipeline by Amgen Inc, H2 2018 195
Melanoma - Pipeline by Angimmune LLC, H2 2018 195
Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2018 196
Melanoma - Pipeline by APEIRON Biologics AG, H2 2018 196
Melanoma - Pipeline by Apexigen Inc, H2 2018 196
Melanoma - Pipeline by Aphios Corp, H2 2018 197
Melanoma - Pipeline by Aposense Ltd, H2 2018 197
Melanoma - Pipeline by Aprea AB, H2 2018 198
Melanoma - Pipeline by Aptose Biosciences Inc, H2 2018 198
Melanoma - Pipeline by Arcus Biosciences Inc, H2 2018 199
Melanoma - Pipeline by ArQule Inc, H2 2018 199
Melanoma - Pipeline by Array BioPharma Inc, H2 2018 200
Melanoma - Pipeline by Asana BioSciences LLC, H2 2018 200
Melanoma - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018 201
Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2018 201
Melanoma - Pipeline by Atreca Inc, H2 2018 201
Melanoma - Pipeline by aTyr Pharma Inc, H2 2018 202
Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018 202
Melanoma - Pipeline by Autolus Therapeutics Plc, H2 2018 203
Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2018 203
Melanoma - Pipeline by Batu Biologics Inc, H2 2018 204
Melanoma - Pipeline by Bayer AG, H2 2018 204
Melanoma - Pipeline by BeiGene Ltd, H2 2018 205
Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2018 205
Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2018 206
Melanoma - Pipeline by BerGenBio ASA, H2 2018 206
List of Figures
Number of Products under Development for Melanoma, H2 2018 85
Number of Products under Development by Companies, H2 2018 86
Number of Products under Development by Universities/Institutes, H2 2018 107
Number of Products by Top 10 Targets, H2 2018 151
Number of Products by Stage and Top 10 Targets, H2 2018 151
Number of Products by Top 10 Mechanism of Actions, H2 2018 166
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 166
Number of Products by Routes of Administration, H2 2018 181
Number of Products by Stage and Routes of Administration, H2 2018 181
Number of Products by Top 10 Molecule Types, H2 2018 183
Number of Products by Stage and Top 10 Molecule Types, H2 2018 183
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017